Literature DB >> 17056465

Uveitic glaucoma and Rosai-Dorfman disease (sinus histiocytosis).

Robert E MacLaren1, Kulwinder S Hundal, Peter Trittibach, Philip A Bloom.   

Abstract

PURPOSE: To report a novel association of uveitic glaucoma with Rosai-Dorfman disease.
METHODS: Case report.
RESULTS: A 67-year-old Caucasian woman presented with a chronic bilateral granulomatous uveitis which did not respond to conventional topical steroid therapy. She also had raised intraocular pressures, glaucomatous optic disc changes and diffuse nodular fibrous skin lesions. Subsequent skin biopsy immuno-cytochemistry showed S-100 staining, consistent with Rosai-Dorfman disease. The uveitis and glaucoma were highly resistant to standard medical treatments, but completely resolved together with the systemic features of the disease after six months.
CONCLUSIONS: Rosai-Dorfman disease has not previously been reported to cause uveitic glaucoma and should be considered in non-responsive cases presenting with a rash. The disease is entirely self-limiting and early diagnosis may therefore avoid unnecessary trabeculectomy and/or systemic immune suppression.

Entities:  

Mesh:

Year:  2006        PMID: 17056465     DOI: 10.1080/09273940600878829

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  3 in total

Review 1.  Rosai-Dorfman disease presenting as choroidal melanoma: a case report and review of the literature.

Authors:  Tersia L Vermeulen; Timothy W Isaacs; Dominic Spagnolo; Benhur Amanuel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-24       Impact factor: 3.117

2.  Extranodal Rosai-Dorfman of the Pancreas Presents with Bilateral Granulomatous Anterior Uveitis.

Authors:  A'sha Brown; Sara V Branson; Ghazala A Datoo O'Keefe
Journal:  Ocul Oncol Pathol       Date:  2018-10-25

3.  Cystoid macular oedema associated with Rosai-Dorfman disease: a case report.

Authors:  Rubens Camargo Siqueira; Antonio Augusto Velasco E Cruz
Journal:  BMC Ophthalmol       Date:  2017-08-14       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.